Showing results (11-20 of 55) with videos related to
Sort By:
Pageof 6
Biochimica Et Biophysica Acta|October 22, 2008
BAR the door: cancer suppression by amphiphysin-like genesGeorge C Prendergast, Alexander J Muller, Arivudanambi Ramalingam, et al.Cancer Research|December 17, 2017
Discovery of IDO1 Inhibitors: From Bench to BedsideGeorge C Prendergast, William P Malachowski, James B DuHadaway, et al.International Journal of Tryptophan Research : IJTR|September 12, 2013
The Tumor-Selective Cytotoxic Agent β-Lapachone is a Potent Inhibitor of IDO1Hollie E Flick, Judith M Lalonde, William P Malachowski, et al.Methods in Cell Biology|July 19, 2025
Matrigel implants embedded with IDVCs (IDO1-dependent vascularizing cells) to study inflammatory neovascularizationShih-Chun Shen, James B DuHadaway, Arpital Mondal, et al.International Review of Cell and Molecular Biology|February 8, 2018
Indoleamine 2,3-Dioxygenase and Its Therapeutic Inhibition in CancerGeorge C Prendergast, William J Malachowski, Arpita Mondal, et al.Trends in Cancer|February 8, 2018
Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'George C Prendergast, Arpita Mondal, Souvik Dey, et al.Nature Medicine|February 16, 2005
Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapyAlexander J Muller, James B DuHadaway, P Scott Donover, et al.Cancer Biology & Therapy|December 22, 2004
Targeted deletion of the suppressor gene bin1/amphiphysin2 accentuates the neoplastic character of transformed mouse fibroblastsAlexander J Muller, James B DuHadaway, P Scott Donover, et al.Frontiers in Immunology|December 6, 2014
IDO2 in Immunomodulation and Autoimmune DiseaseGeorge C Prendergast, Richard Metz, Alexander J Muller, et al.Cancer Research|February 18, 2010
Immunotherapeutic suppression of indoleamine 2,3-dioxygenase and tumor growth with ethyl pyruvateAlexander J Muller, James B DuHadaway, Daniel Jaller, et al.Pageof 6